Robin van geel

University of Maastricht

Netherlands

Research Interests

Explore related searches

Professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (11)

Fabienne Magdelijns

Head of the subdivision of the General Internal Medicine department

Maastricht University Medical Centre

NETHERLANDS

View details

Mariana Brandão

Institut Jules Bordet

BELGIUM

View details

Judith Gulikers

UCSF Cardiovascular Research Institute

NETHERLANDS

View details

Sander Rensen

Associate professor

University of Maastricht

NETHERLANDS

View details

Martina Bortolot

Università degli Studi di Udine

ITALY

View details

Janine Ziemons

University of Maastricht

NETHERLANDS

View details

Johanna Driessen

University of Maastricht

NETHERLANDS

View details

Judith de Vos-Geelen

Maastricht University Medical Centre

NETHERLANDS

View details

Rob ter Heine

NETHERLANDS

View details

David Barnett

University of Maastricht

NETHERLANDS

View details

Ardy van Helvoort

Associate Professor

University of Maastricht

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Robin van geel

Research Interests

Explore related searches

Contact this professor

Articles (10)

De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence?

The gut microbiota during tamoxifen therapy in patients with breast cancer

Prebiotic fibre mixtures counteract the manifestation of gut microbial dysbiosis induced by the chemotherapeutic 5-Fluorouracil (5-FU) in a validated in vitro model of the colon

Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC

Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer

Intra-Individual Variability of Direct Oral Anticoagulant Levels in Frail Older Patients upon, during, and after Acute Hospitalization: the DOAC-FRAIL Study

Proactive monitoring of drug–drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer

Systematic Evaluation of Osimertinib Population Pharmacokinetic Models in a Cohort of Dutch Adults with Non-Small Cell Lung Cancer

A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer

Development and validation of an HPLC–MS/MS method to simultaneously quantify brigatinib, lorlatinib, pralsetinib and selpercatinib in human K2‐EDTA plasma

Collaborators (11)

Fabienne Magdelijns

Mariana Brandão

Judith Gulikers

Sander Rensen

Martina Bortolot

Janine Ziemons

Johanna Driessen

Judith de Vos-Geelen

Rob ter Heine

David Barnett

Ardy van Helvoort

Make your next move.